文献速递血液透析通路

动静脉瘘建立后短期死亡率和促进成熟的修正手术

Short-term mortality and revisions to promote maturation after arteriovenous fistula creation.
PubMed 文献 · J Vasc Surg · 2023-12-12

该单中心回顾性研究纳入2017年5月至2020年11月期间创建的250例动静脉瘘(AVF),发现2年生存率为82%,22%患者接受了AVF修正手术。体弱或非常体弱者在复合终点(REVDEAD)组中更多(60% vs 48%,P=0.05),校正后体弱使REVDEAD的比值增加1.9倍(95%CI 1.1-3.3)。前臂AVF比上臂AVF更可能需要修正(P=0.05)。

要点

  • AVF创建后2年生存率为82%,22%(54例)患者接受了AVF修正手术。
  • 体弱或非常体弱者更易达到REVDEAD复合终点(60% vs 48%,P=0.05)。
  • 校正后体弱使REVDEAD的比值增加1.9倍(95%CI 1.1-3.3)。

核心结论

  • 体弱患者接受AVF后2年内死亡风险显著更高,而体弱与促进成熟的修正手术需求之间无显著关联。
  • 前臂AVF比上臂AVF更可能需要修正;对于体弱、2年死亡可能性高的患者,移植血管可能比AVF更合适。
  • 若考虑在体弱患者中建立AVF,应优先选择上臂AVF而非前臂AVF。

研究设计与样本

  • 单中心回顾性综述,纳入2017年5月至2020年11月期间创建的250例AVF。
  • 成熟定义为外科医生认为AVF可供使用或患者成功使用AVF进行透析的日期。
  • 使用风险分析指数(Risk Analysis Index)计算体弱程度。
  • 主要结局为AVF创建后2年内促进成熟的血管内/外科修正和/或死亡的复合终点(REVDEAD)。
  • REVDEAD与未达到主要结局者(NOREVDEAD)进行比较。

主要发现

  • AVF创建后2年生存率为82%,54例(22%)患者接受了AVF修正;其中31例(59%)患者进展至AVF成熟。
  • 250例AVF中,91例(36%)达到REVDEAD主要结局,159例(64%)未达到(NOREVDEAD)。
  • REVDEAD与NOREVDEAD两组在年龄(P=0.18)、性别(P=0.75)、白人种族(P=0.97)、西班牙裔(P=0.62)、肥胖(P=0.76)、冠状动脉疾病(P=0.07)、充血性心力衰竭(P=0.29)、糖尿病(P=0.78)、慢性阻塞性肺疾病(P=0.10)、透析状态(P=0.63)、高血压(P=0.32)、外周动脉疾病(P=0.34)或心律失常(P=0.13)方面均无差异。
  • 两组在前臂与上臂AVF位置(P=0.42)或静脉直径(P=0.58)方面无差异;前臂通路相比上臂AVF创建与更高的成熟前修正率相关(P=0.05)。
  • REVDEAD组中体弱或非常体弱者更多(60% vs 48%,P=0.05);成熟AVF中,REVDEAD组成熟所需时间更长(110.0±9.1天 vs 78.8±5.6天,P=0.003)。

临床怎么用

  • 对于体弱、2年死亡可能性高的患者,移植血管可能比AVF更合适(作者认为)。
  • 若考虑在体弱患者中建立AVF,应优先选择上臂AVF而非前臂AVF(作者建议)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Arteriovenous fistula (AVF) for hemodialysis access is traditionally considered superior to grafts due to infection resistance and purported improved patency. However, challenges to AVF maturation and limited patient survival may reduce AVF benefits. The objective of this study is to identify factors associated with risk of AVF requiring revision before maturation and/or mortality within 2 years of creation. METHODS: We performed a retrospective review of 250 AVFs created between May 2017 and November 2020 at a single institution. Maturation was defined as the date the surgeon deemed the AVF ready for use or the patient successfully used the AVF for dialysis. The Risk Analysis Index was used to calculate frailty. The primary outcome was a composite of endovascular/surgical revision to promote maturation and/or mortality within 2 years of AVF creation (REVDEAD). The primary outcome was categorized as met if the patient required a revision to promote maturation or if the patient experienced mortality within 2 years of AVF creation, or if both occurred. REVDEAD was compared with those who did not meet the primary outcome and will be referred to as NOREVDEAD. RESULTS: Survival at 2 years after AVF creation was 82%, and 54 (22%) patients underwent AVF revision. Of those, 31 (59%) patients progressed to AVF maturation. Of the 250 AVFs, 91 (36%) met the primary outcome of REVDEAD and 159 (64%) did not (NOREVDEAD). There was no difference between the REVDEAD and NOREVDEAD groups in age (P = .18), sex (P = .75), White race (P = .97), Hispanic ethnicity (P = .62), obesity (P = .76), coronary artery disease (P = .07), congestive heart failure (P = .29), diabetes mellitus (P = .78), chronic obstructive pulmonary disease (P = .10), dialysis status (P = .63), hypertension (P = .32), peripheral arterial disease (P = .34), or dysrhythmia (P = .13). There was no difference between the groups in the forearm vs the upper arm location of AVF (P = .42) or the vein diameter (P = .58). Forearm access, as opposed to upper arm AVF creation, was associated with higher rate of revision before maturation (P = .05). More patients in REVDEAD were frail or very frail (60% vs 48%, P = .05). Of the AVFs that matured, maturation required longer time in REVDEAD at 110.0 ± 9.1 days vs 78.8 ± 5.6 days (mean ± standard deviation) (P = .003). Adjusted for the vein diameter and the forearm vs the upper arm, frailty increased the odds of REVDEAD by 1.9 (95% confidence interval: 1.1, 3.3). CONCLUSIONS: Frail patients who underwent AVF were significantly more likely to die within 2 years of AVF creation with no significant association between frailty and the need for revisions to promote maturation. Forearm AVFs were more likely to require revisions; in patients who are frail, with a high likelihood of 2-year mortality, graft may be more appropriate than AVF. If AVF is being considered in a frail patient, upper arm AVFs should be prioritized over forearm AVFs.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Wang KM, Gelabert H, Jimenez JC, et al. Short-term mortality and revisions to promote maturation after arteriovenous fistula creation. J Vasc Surg. 2023. PMID: 38092309. doi:10.1016/j.jvs.2023.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。